The Presymptomatic Era: Operationalizing Early Detection for Type 1 Diabetes

For most of the last century, Type 1 Diabetes announced itself with an acute crisis. A child gets sick, sometimes critically sick, and the diagnosis arrives in the emergency department. The standard clinical response is therefore reactive: wait for symptoms to appear, manage the acute crisis – often Diabetic Ketoacidosis (DKA) – and then initiate lifelong insulin therapy. And here is the uncomfortable part: the autoantibody tests that can identify T1D years before symptoms have been broadly available for more than 15 years. Yet 85–90% of patients are still diagnosed at stage 3, in clinical distress.

The science of finding T1D early is settled. What is not settled is how to get it done.

At our recent webinar, clinical leaders Dr. Michael J. Haller (Professor and Chief of Pediatric Endocrinology, University of Florida; Chair of TrialNet), Dr. Monica Bianco (Pediatric Endocrinologist, Lurie Children’s Hospital), and Dr. Melissa Putman (Adult & Pediatric Endocrinologist, Mass General Hospital) joined us to outline how new screening technologies, virtual clinical models, and disease-modifying therapies are transforming T1D from an inevitable acute diagnosis into a manageable, delayable, and ultimately preventable condition.

As Dr. Monica Bianco put it:

“It’s not a question of whether or not we should screen people. It’s how we’re going to do it, and whether our healthcare systems can reliably support the number of people identified through screening.”

Here are the key takeaways and actionable strategies from their discussion on how we can operationalize general population screening and build a proactive care model:

 

1. Why the current guidelines fall short

Today’s screening recommendations start with family history. Those who have a first-degree relative with a T1D diagnosis get tested first. This makes sense, as 1 in 20 test positive, versus roughly 1 in 300 in the general population.

However, 90% of newly diagnosed T1D patients have no family history of the disease at all. A screening strategy anchored to family history is, by design, a strategy that misses nine out of ten future patients. Furthermore, the guidelines depend on information that, in most health systems, is sparsely documented.

Guidelines alone were never going to be enough. Finding these patients before it’s too late requires systemic screening of a much broader population.

 

2. What changed the math: therapeutics

If early detection has been possible for 15 years, why is momentum building now? Because newly approved therapeutic interventions mean a positive test leads somewhere.

Screening is no longer just a precaution. It is an actionable clinical undertaking that makes the preservation of beta cells and the avoidance of critical complication possible. Above all, it gives families time to prepare, and to educate before clinical onset. Dr. Melissa Putman put it best:

“Between the ages of 18 and 23 is a critical life stage in young adulthood… if there’s anything we can do in that window of time to push off the diagnosis until those frontal lobes have had more of a chance to mature, I think that we should.”

 

3. Better care, and better economics for all

Not only is a DKA event traumatic for patients and their families, a single admission can cost a health system between $75,000 and $100,000. Finding patients before a crisis impacts not only the patient’s quality of life, but also the short and long term costs to both the patient and the system.

“We know that we can convert those DKA rates at diagnosis from 40, even 50 or 60 percent in some populations, to the low single digits if we can identify folks through screening, autoantibody testing, and then monitoring.” – Dr. Michael Haller

The same math works for payers. Reimbursement and a potential spike in denial rates are a concern with any large-scale screening program, but avoided ICU admissions are real savings, and that case can be made proactively. Dr. Haller’s statewide program in Florida shows what that looks like in practice. The program de-risked the costs up front: state funding and Breakthrough T1D support cover prepaid screening kits, so families carry no cost risk. It also tracked claims data expecting denials to pile up. They have not. Denials have run in the low single digits, zero when another autoimmune condition is documented. To make this work at true population scale, however, payers need to be engaged sooner, and the value of avoided ICU admissions quantified.

 

4. The implementation playbook

None of this happens by simply ordering more tests. For health systems considering a screening program, the panelists offered hard-won guidance on where to start and how to get it right.

Screen where patients already are.

General population screening lives or dies in primary care. Venous draws for a disease a family has never heard of are a hard sell. Capillary dried blood spot testing that piggybacks on finger sticks already happening at well-child visits (lead screens, lipid panels, hemoglobin checks) is not. Dr. Haller’s ideal schedule is “three shots on goal”, at ages 2, 6, and 12, timed to the known waves of seroconversion in childhood. And a negative result carries real information:

“If you had three antibody tests and they were all negative, you know more about your type 1 risk than most first-degree relatives do. By definition, your risk is really, really low at that point.” – Dr. Michael Haller

Ask primary care to find, not to manage.

Pediatricians may be hesitant to order a test if a positive result becomes their problem to own. The programs that work remove that burden entirely.

“I personally don’t think it’s reasonable or appropriate to ask a general pediatrician, who has to know and take care of every diagnosis under the sun, to do anything more than identify these kids early on. If they do just that, they are knocking it out of the park.” – Dr. Michael Haller

In Florida, a positive screen triggers referral to a virtual early-stage T1D clinic, where specialists handle confirmatory testing, family education, and longitudinal monitoring, largely by telemedicine. The hub-and-spoke model also solves the capacity problem endocrinology practices consistently raise: early-stage, stable patients do not need to consume scarce in-person specialist slots.

Treat adults as the other half of the problem, because they are.

More than half of new T1D diagnoses occur in adults, where the disease progresses more slowly and is routinely mistaken for Type 2.

“The knee-jerk when you get an A1C in that pre-diabetes range is, yes, it’s Type 2, diet and exercise… A lot of adults with type 1 actually are misdiagnosed as type 2. Part of that is it’s not on our radar, but it’s also that type 1 in adults can be slower in onset, with more preserved beta cell function for a longer period. It looks a little different, so we need to think about it differently when we’re thinking about screening.” — Dr. Melissa Putman

Because universal screening of all adults is operationally difficult, Dr. Putman recommends targeting adults with new-onset pre-diabetes or borderline A1C to distinguish slowly progressing T1D from Type 2. Here, the window for intervention is open and the yield is high. Once identified, these patients need different management: closer monitoring, CGM, ketone education, and avoidance of inappropriate therapies like metformin.

Make equity a design requirement, not an afterthought.

As we scale these innovations, the work cannot live only in elite academic medical centers. Florida has proven the model travels: federally qualified health centers there have built antibody screening into standard well-child care, with some clinics processing more than 500 screens a month.

“We have to continuously think about equitable implementation. People with access to academic centers are getting early detection and advanced therapies way earlier than those who do not, and that discrepancy is getting bigger with every advance we make.” – Dr. Monica Bianco

Conclusion: A call to action – practicing medicine before the diagnosis

Taken together, the screening schedules, care pathways, and payer strategies all point to the same underlying change, one Dr. Bianco named directly:

“We’re used to saying, you have this diagnosis and here is your treatment. Now it’s: you are at risk for this, and we have something that can delay when we have to utilize all of our treatment options. That is a big shift.”

Presymptomatic medicine asks health systems to do things they were not built to do: find people who feel fine, route them to the right care pathway, monitor them over years, and coordinate seamlessly between primary care and specialty teams. The barrier is no longer the science, and it is not the data, which already sits in the systems clinicians use every day. The barrier is delivery. Health systems that build that delivery muscle for T1D will find it is the same muscle needed for every early-detection opportunity that follows.

T1D is at the forefront of a shifting paradigm. The question for health system leaders is no longer whether to screen. It is whether your organization will be ready when screening becomes the standard of care.

Watch the full conversation

The complete webinar recording, including the audience Q&A, is available at lucemhealth.com/t1d-webinar.